Details:
Synaffix will provide all proprietary ADC technologies, including GlycoConnect™, HydraSpace™, and select toxSYN™ linker-payloads. Kyowa Kirin will leverage its innovative antibody-based therapeutics pipeline to develop a portfolio of ADCs with optimized therapeutic index.
Lead Product(s): Antibody-drug Conjugate Therapeutic
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Undisclosed Product Type: Large molecule
Partner/Sponsor/Collaborator: Kyowa Kirin
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement August 04, 2021
Details:
Under the agreement, Immunomedics gains commercial rights for application of ProteoNic’s technology platform to the development of specified proprietary products from mammalian cells.
Lead Product(s): Recombinant protein
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Undisclosed Product Type: Large molecule
Partner/Sponsor/Collaborator: Immunomedics
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement October 20, 2020
Details:
Under the expanded collaboration, ADC Therapeutics has been granted non-exclusive rights for two additional programs, which brings the total number of programs using Synaffix’ ADC technologies to five.
Lead Product(s): Antibody-drug conjugates
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Undisclosed Product Type: Large molecule
Partner/Sponsor/Collaborator: ADC Therapeutics
Deal Size: $54.0 million Upfront Cash: Undisclosed
Deal Type: Collaboration July 23, 2020
Details:
Under the agreement and using its CHO.RiGHT™ expression platform, ProBioGen will conduct cell line development of a ?? T-cell engaging bispecific antibody format.
Lead Product(s): Vγ9Vδ2 T cells based antibodies
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Undisclosed Product Type: Large molecule
Partner/Sponsor/Collaborator: ProBioGen
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement January 14, 2020
Details:
Miracogen has been granted non-exclusive rights to Synaffix’s proprietary GlycoConnect™ and HydraSpace™ ADC technologies for use in this second clinical candidate.
Lead Product(s): Antibody drug conjugate linker
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Undisclosed Product Type: Undisclosed
Partner/Sponsor/Collaborator: Shanghai Miracogen
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement January 07, 2020